within Pharmacolibrary.Drugs.ATC.M;

model M03BC51
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 1.3333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600,            
    Vdp             = 0.09,
    k12             = 2,
    k21             = 2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M03BC51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties, used primarily for the relief of discomfort associated with acute, painful musculoskeletal conditions. The combinations (ATC code M03BC51) typically pair orphenadrine with analgesics such as paracetamol or aspirin. Its use has declined due to side effects, but it is still available and approved in some countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated based on available data for orphenadrine (oral administration) in healthy adults, as no specific PK parameters for the combination products have been published.</p><h4>References</h4><ol><li><p>Stanko, JR (1990). Review of oral skeletal muscle relaxants for the craniomandibular disorder (CMD) practitioner. <i>Cranio : the journal of craniomandibular practice</i> 8(3) 234–243. DOI:<a href=&quot;https://doi.org/10.1080/08869634.1990.11678317&quot;>10.1080/08869634.1990.11678317</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2083431/&quot;>https://pubmed.ncbi.nlm.nih.gov/2083431</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M03BC51;
